KR102012025B1 - 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질 - Google Patents

세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질 Download PDF

Info

Publication number
KR102012025B1
KR102012025B1 KR1020157006439A KR20157006439A KR102012025B1 KR 102012025 B1 KR102012025 B1 KR 102012025B1 KR 1020157006439 A KR1020157006439 A KR 1020157006439A KR 20157006439 A KR20157006439 A KR 20157006439A KR 102012025 B1 KR102012025 B1 KR 102012025B1
Authority
KR
South Korea
Prior art keywords
leu
ifnα
fusion protein
glu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157006439A
Other languages
English (en)
Korean (ko)
Other versions
KR20150063375A (ko
Inventor
배용수
홍승호
김영훈
한승수
김진
Original Assignee
제이더블유크레아젠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이더블유크레아젠 주식회사 filed Critical 제이더블유크레아젠 주식회사
Publication of KR20150063375A publication Critical patent/KR20150063375A/ko
Application granted granted Critical
Publication of KR102012025B1 publication Critical patent/KR102012025B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020157006439A 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질 Expired - Fee Related KR102012025B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120088610 2012-08-13
KR1020120088610 2012-08-13
PCT/KR2013/007136 WO2014027789A1 (ko) 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질

Publications (2)

Publication Number Publication Date
KR20150063375A KR20150063375A (ko) 2015-06-09
KR102012025B1 true KR102012025B1 (ko) 2019-08-19

Family

ID=50685640

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157006439A Expired - Fee Related KR102012025B1 (ko) 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질

Country Status (6)

Country Link
US (1) US9682152B2 (https=)
JP (1) JP6010227B2 (https=)
KR (1) KR102012025B1 (https=)
CN (1) CN104583240B (https=)
IN (1) IN2015DN01371A (https=)
WO (1) WO2014027789A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987381B (zh) * 2015-06-11 2018-11-27 吉林大学 重组正电荷多肽干扰素及在抗肿瘤和抗病毒治疗中的应用
EP4034146A4 (en) * 2019-09-26 2024-03-06 Orionis Biosciences, Inc. CONJUGATED CHIMERIC PROTEINS
KR20230099956A (ko) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 면역세포에 항원을 전달하기 위한 폴리펩타이드
CN114853911B (zh) * 2022-05-23 2024-06-28 复旦大学 三叶因子2/干扰素α2融合蛋白及其防治病毒感染性疾病的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US20120134961A1 (en) * 2009-03-27 2012-05-31 Jw Pharmaceutical Corporation Interferon-alpha (IFN-alpha) Fused Protein Having IFN-alpha and Cytoplasmic Transduction Peptide (CTP)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097671A1 (en) 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
MX2008002015A (es) 2005-08-15 2008-03-25 Hoffmann La Roche Polietilenglicol-interferon alfa y ribavirina para el tratamiento del virus de hepatitis b.
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
KR101183826B1 (ko) * 2009-03-27 2012-09-18 제이더블유중외제약 주식회사 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
CN101942026B (zh) * 2010-10-14 2014-08-27 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US20120134961A1 (en) * 2009-03-27 2012-05-31 Jw Pharmaceutical Corporation Interferon-alpha (IFN-alpha) Fused Protein Having IFN-alpha and Cytoplasmic Transduction Peptide (CTP)

Also Published As

Publication number Publication date
US20150202312A1 (en) 2015-07-23
JP6010227B2 (ja) 2016-10-19
WO2014027789A1 (ko) 2014-02-20
CN104583240B (zh) 2017-11-28
JP2015526084A (ja) 2015-09-10
CN104583240A (zh) 2015-04-29
KR20150063375A (ko) 2015-06-09
US9682152B2 (en) 2017-06-20
IN2015DN01371A (https=) 2015-07-03

Similar Documents

Publication Publication Date Title
US11034731B2 (en) Stabilized soluble pre-fusion RSV F polypeptides
JP6722227B2 (ja) ヘプシジン類似体及びその使用
JP6608799B2 (ja) 高可溶性レプチン
KR102129235B1 (ko) 글루카곤 유사체
KR20190039889A (ko) Peg화된 돼지 인터페론 및 그의 사용 방법
CN101255197A (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
CN103237808A (zh) 抗癌融合蛋白
KR20090101908A (ko) 인터페론 알파 돌연변이체 및 이의 폴리에틸렌 글리콜 유도체
KR102012025B1 (ko) 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질
CN107108712A (zh) 提高重组蛋白产量的方法
Ji et al. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β
JP5576928B2 (ja) インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むＩＦＮ−α融合タンパク質
CN106554409B (zh) 一种长效胰高血糖素样肽-1类似物及其应用
CA2348308A1 (en) Rantes-derived peptides with anti-hiv activity
CN102584979B (zh) PEG化干扰素λ
JPH10330284A (ja) 肝細胞保護剤
CN114245802B (zh) 修饰的il-2蛋白、peg偶联物及其用途
KR20200080331A (ko) 글루카곤 유사체
KR101183826B1 (ko) 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
WO2026055636A1 (en) Peptides and compositions for improving glucose levels
HK40071141A (en) Modified il-2 proteins, peg conjugates, and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220813

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220813

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000